M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

Phase 2

Terminated

Conditions: Hematological Malignancies
Leukemia
Myelodysplastic Syndrome
Lymphoma

Interventions: Drug: Mycophenolate Mofetil (MMF)
Drug: Thymoglobulin
Drug: Sirolimus
Procedure: Stem Cell Transplant

First Posted Date: 2007-07-25

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00506948

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: Campath-1H
Drug: G-CSF
Drug: GM-CSF
Drug: BCNU
Drug: Stem Cell Transplant
Drug: Preparative Regimen for Allogenic Stem Cell Transplantation
Drug: Cytarabine
Drug: Etoposide
Drug: Melphalan
Drug: Campath
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Low dose total body irradiation

First Posted Date: 2007-07-25

Last Posted Date: 2011-11-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00505921

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

A Mood Management Intervention for Pregnant Smokers

Completed

Conditions: Smoking
Pregnancy

Interventions: Behavioral: Health & Wellness Intervention
Behavioral: Questionnaire
Behavioral: Mood Management Intervention

First Posted Date: 2007-07-25

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 338

Registration Number: NCT00505869

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients

Not Applicable

Completed

Conditions: Melanoma

Interventions: Drug: Fibrin Sealant

First Posted Date: 2007-07-25

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00506311

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Vibration Response Imaging (VRI) in Lung Cancer Patients

Completed

Conditions: Lung Cancer

Interventions: Procedure: Vibration Response Imaging

First Posted Date: 2007-07-25

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT00506467

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Feasibility Study of Collecting Multicenter Chronic GVHD Data

Completed

Conditions: Graft-Versus-Host Disease

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-07-25

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00506233

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Melatonin Postoperative Sleep Study in Breast Cancer Patients

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Melatonin
Behavioral: Questionnaire

First Posted Date: 2007-07-25

Last Posted Date: 2012-12-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT00506064

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: Busulfan
Drug: Fludarabine

First Posted Date: 2007-07-25

Last Posted Date: 2012-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 82

Registration Number: NCT00506857

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Erwinase Study in Patients With Acute Lymphoblastic Leukemia

Not Applicable

Completed

Conditions: Leukemia

Interventions: Drug: Erwinase

First Posted Date: 2007-07-25

Last Posted Date: 2014-09-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT00506597

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

Phase 1

Terminated

Conditions: Uterine Cancer

Interventions: Drug: Imatinib Mesylate
Drug: Paclitaxel

First Posted Date: 2007-07-25

Last Posted Date: 2020-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17

Registration Number: NCT00506779

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy